Global Markets

From Sartorius to VC, Dynamk’s new MD talks life science investment

AI, regenerative medicine enabling technologies, and clinical diagnostics are major investment opportunities, says life science executive Reinhard Vogt who has joined Dynamk Capital. Reinhard Vogt served as an executive at Sartorius AG for over 35 years. During his tenure, he was responsible for the strategic development of the firm’s Bioprocess Division that grew from around $30 Million to around $1.2 billion today, reached through a combination of strong organic growth and a strong focus on M&A and the integration of…

Charles River CRO to continue to expand biomanufacturing support biz

Following a strong year for its manufacturing services division, Charles River Laboratories intends to invest further to benefit from the high growth in biologics. Contract Research Organization (CRO) Charles River reported full year 2018 revenues of $430 million (€381 million) within its manufacturing support division, up 11.9% on the previous year. The unit provides manufacturing services for drug developers, including cell line characterization, lot release testing and stability studies. Increasingly, the business has focused on biologics, reflecting industry’s shifting pipelines,…

Samsung Bioepis inks biosimilar deals to enter China

Samsung Bioepis has teamed with C-Bridge Capital to bring its third-wave biosimilars to the Chinese market. C-Bridge will establish a new company, AffaMed Therapeutics, under terms of the deal, and will license multiple biosimilar candidates from Samsung Bioepis to commercialize in China. These include the third-wave biosimilar candidates SB11 and SB12 – versions of Roche/Novartis’ Lucentis (ranibizumab) and Alexion’s Soliris (eculizumab) – and SB3, a biosimilar of Roche’s Herceptin (trastuzumab). The deal comes weeks after a partnership deal with 3SBio…

VBAs and marketing campaign to aid RNAi Onpattro ramp up, says Alnylam

Around 200 patients have so far been treated with Onpattro (patisiran), the first approved RNA interference (RNAi) drug, bringing in $12.5 million for Alnylam. In August 2018, the US Food and Drug Administration (FDA) and the European Commission (EC) approved Alnylam Pharmaceuticals’ Onpattro for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. The approvals heralded in a new class of drugs: small interfering ribonucleic acid (siRNA) treatments. Onpattro works by silencing a portion of RNA involved…

Roche looks to delivery device to keep Lucentis biosimilars at bay

Roche says its Port Delivery System will keep Lucentis (ranibizumab) competitive against upcoming biosimilar competition. Lucentis pulled in CHF 1.66 billion ($1.66 billion) in US sales for Roche in 2018, up 18% on the year before. The drug is marketed in Europe by fellow Swiss firm Novartis. The firm attributed the increase to the “ongoing rollout of prefilled syringes and sales increases in all approved indications.” The monoclonal antibody, approved for eye conditions including neovascular (‘wet’) age-related macular degeneration, macular…

Madison expansion will add commercial capacity, says Catalent

Plans to invest $200 million laid down last year will put Catalent in a position to offer commercial manufacturing from its Madison, Wisconsin facility, the CDMO says. In November 2018, contract development and manufacturing organization (CDMO) Catalent announced its intentions to invest across its two biomanufacturing sites. The board laid down plans to plough $100 million (€88 million) into its Madison, Wisconsin plant to add a fourth and fifth biomanufacturing train. During Catalent’s second quarter FY2019 financial call this week,…

Pfizer looks to oncology biosimilars to break US market

Biosimilar uptake in the US has been stifled in the inflammation and immunology (I&I) space but Pfizer expects a different dynamic for oncology products. Pfizer’s biosimilar business had a robust year in 2018. The firm reported a 41% operational growth in the sector over the year prior, with total sales of $769 million (€674 million). The company attributed much of this growth to sales of Inflectra, its version of J&J’s Remicade (infliximab), which pulled in $642 million worldwide including $259…

Vendors highlight another standout year for bioprocessing

Demand for bioprocessing technology remains strong as GE Healthcare, Thermo Fisher, Pall and Sartorius all report high annual growth. With the financial season in full swing, four of the major industry suppliers have reported their Q4s and end-of-year results, and all have one thing in common: high growth across their bioprocessing segments. GE Healthcare, which is being prepped to separate from parent company General Electric, reported revenues of $19 billion (€16.5 billion) for the full year, up 4%. The division…

Novartis: Manufacturing volumes a barrier to $10bn insulin space

The manufacturing volumes needed to succeed in the insulin market are huge says Novartis, fresh from entering the space through a biosimilars partnership. Late last year, Swiss pharma firm Novartis, through its division Sandoz, partnered with Chinese manufacturer Gan & Lee in an effort to bring biosimilar insulins to the US and Europe. Sandoz told this publication at the time that Gan & Lee’s production capacity, “with attractive cost of goods sold structures,” was a major driver to the collaboration.…

Global Humira sales near $20bn, but expect decline in 2019

Looking to 2019, AbbVie says US sales of its bestseller monoclonal antibody Humira (adalimumab) will continue to grow but expects a $2 billion hit from biosimilar competition. For the full year 2018, AbbVie reported total sales of $32.8 billion (€28.7 billion), comprising $19.9 billion in sales of the world’s most successful drug by revenue, Humira (adalimumab). This represented a 7.4% year-on-year growth for the monoclonal antibody (MAb). But for AbbVie, 2018 was tainted by the approval and launch of several…